z-logo
Premium
Pharmacokinetics of cefaronide, ceftriaxone and cefoperazone in sheep
Author(s) -
GUERRINI V. H.,
FILIPPICH L. J.,
CAO G. R.,
ENGLISH P. B.,
BOURNE D. W. A.
Publication year - 1985
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1985.tb00935.x
Subject(s) - ceftriaxone , cefoperazone , pharmacokinetics , cephalosporin , medicine , pharmacology , microbiology and biotechnology , antibiotics , biology , imipenem , antibiotic resistance
Guerrini, V.H., Filippich, L.J., Cao, G.R., English, P.B. & Bourne, D.W.A. Pharmacokinetics of cefaronide, ceftriaxone and cefoperazone in sheep. J. vet. Pharmacol. Therap. 8, 120–127. The pharmacokinetics of cefaronide (16gm/kg dose), ceftriaxone and cefoperazone (47gm/kg dose), after intravenous (i.v.) administration were determined in six Merino ewes. The mean values for terminal half life, steady state volume of distribution V d(ss) , renal clearance (Cl R ) and total body clearance (Cl B ) for cefaronide were 1.5 h, 0.39l/kg, 0.06l/h/kg and 0.16l/h/kg, for ceftriaxone; 1.7 h, 0.30l/kg, 0.08l/h/kg, and 0.22l/h/kg, and 0.7 h, 0.16l/kg, 0.02l/h/kg and 0.16l/h/kg for cefoperazone, respectively. After 5.5 h, approximately 42% cefaronide, and after 8 h, approximately 37% ceftriaxone and 13% cefoperazone, was excreted in urine. The non‐renal elimination of ceftriaxone and cefoperazone appeared to be more rapid in sheep than is reported in man. Cefaronide was excreted largely unchanged in the urine of sheep. Therefore, the elimination of cefaronide in sheep was similar to that found in man. Cefaronide was well distributed in sheep, whereas ceftriaxone and cefoperazone appeared to be distributed to a lesser degree. These Findings underline the different disposition of drugs in different species. Dr V. H. Guerrini, Department of Pharmacy, University of Queensland, St Lucia, QLD 4067, Australia.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here